Eli Lilly and Company (NYSE:LLY) Shares Down 1.1% – What’s Next?

Eli Lilly and Company (NYSE:LLY) was down 1.1% during mid-day trading on Monday. The stock traded as low as $1,239.10 and last traded at $1,242.7580. 1,947,631 shares traded hands during trading, a decline of 34% from the average daily volume of 2,949,663 shares. The stock had previously closed at $1,257.03.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Goldman Sachs raised its price target to $1,413 from $1,371 and maintained a Buy rating, citing expectations for a third-quarter earnings beat and a potential outlook increase. The firm pointed to stronger Mounjaro growth outside the United States and higher Zepbound volumes, including support from Medicare’s GLP-1 Bridge program. Eli Lilly Gains 4.6% as Goldman Sachs Lifts Price Target to $1,413
• Positive Sentiment: Lilly signed agreements in Abu Dhabi covering local packaging of weight-loss medicines and advanced pharmaceutical contract manufacturing with Mubadala Bio. The arrangements could expand regional supply-chain capacity and improve access to Lilly’s fast-growing obesity treatments. Eli Lilly signs Abu Dhabi deal for local packaging of weight-loss medicines
• Positive Sentiment: A potential $1.1 billion drug-delivery collaboration with China’s Metis TechBio adds another technology and pipeline catalyst, although the deal’s value appears contingent on development and commercial milestones. China’s startup Metis TechBio strikes drug-delivery deal worth $1.1 billion with Eli Lilly
• Positive Sentiment: Positive pediatric data for Omvoh showed that half of Week 12 responders with ulcerative colitis remained in clinical remission at Week 52, supporting a possible expansion of Lilly’s inflammatory bowel disease franchise if regulators approve the indication. Is Pediatric Ulcerative Colitis Data Altering the Investment Case for Lilly?

Analysts Set New Price Targets

Several research firms have recently commented on LLY. Wells Fargo & Company boosted their price target on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $1,500.00 price objective on shares of Eli Lilly and Company in a research report on Monday, October 12th. TD Cowen reaffirmed a “buy” rating and set a $1,250.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, September 22nd. Weiss Ratings upgraded Eli Lilly and Company from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, October 15th. Finally, HSBC boosted their target price on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the stock a “reduce” rating in a report on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,314.93.

Eli Lilly and Company Trading Up 3.6%

The company has a market capitalization of $1.21 trillion, a price-to-earnings ratio of 43.14, a P/E/G ratio of 1.65 and a beta of 0.46. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The company’s 50 day simple moving average is $1,181.79 and its two-hundred day simple moving average is $1,114.16.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.40 by $1.98. The business had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business’s revenue for the quarter was up 47.7% on a year-over-year basis. During the same period in the previous year, the company earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, research analysts anticipate that Eli Lilly and Company will post 33.56 earnings per share for the current fiscal year.

Insider Transactions at Eli Lilly and Company

In related news, EVP Patrik Jonsson sold 6,500 shares of the business’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. The trade was a 10.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the transaction, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,500 shares of company stock valued at $15,958,170 in the last quarter. 0.14% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Eli Lilly and Company

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LLY. Maseco LLP raised its holdings in Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after purchasing an additional 28 shares in the last quarter. Marshall & Sterling Wealth Advisors Inc. lifted its position in Eli Lilly and Company by 60.0% in the first quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock valued at $37,000 after purchasing an additional 15 shares during the period. AlphaCentric Advisors LLC acquired a new stake in Eli Lilly and Company in the first quarter valued at about $42,000. Caitlin John LLC purchased a new stake in Eli Lilly and Company in the 2nd quarter valued at approximately $64,000. Finally, IMG Wealth Management Inc. boosted its holdings in Eli Lilly and Company by 500.0% in the 2nd quarter. IMG Wealth Management Inc. now owns 60 shares of the company’s stock valued at $72,000 after purchasing an additional 50 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.